+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Diabetic Macular Edema Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767535
  • Report
  • April 2019
  • Region: Global
  • 306 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Aerpio Therapeutics Inc
  • Alimera Sciences Inc
  • Allergan Plc
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • MORE
The global clinical trial report- “2019 Diabetic Macular Edema Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Diabetic Macular Edema. It presents in-depth analysis of Diabetic Macular Edema clinical trials across markets and companies. The research work is for providing complete understanding into trends in Diabetic Macular Edema.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Diabetic Macular Edema clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Diabetic Macular Edema

The research work is prepared through extensive and continuous research on Diabetic Macular Edema trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Diabetic Macular Edema patients are identified
  • The report includes panorama of Diabetic Macular Edema clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Diabetic Macular Edema clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aerpio Therapeutics Inc
  • Alimera Sciences Inc
  • Allergan Plc
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Diabetic Macular Edema Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Diabetic Macular Edema Clinical Trials by Region
2.2.2 Average Enrollment of Diabetic Macular Edema Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Diabetic Macular Edema Treatment, 2019

3. Region wise Diabetic Macular Edema Clinical Trials
3.1 Asia Pacific Diabetic Macular Edema Clinical Trials by Country
3.2 Europe Diabetic Macular Edema Clinical Trials by Country
3.3 North America Diabetic Macular Edema Clinical Trials by Country
3.4 Middle East and Africa Diabetic Macular Edema Clinical Trials by Country
3.5 South and Central America Diabetic Macular Edema Clinical Trials by Country

4. Diabetic Macular Edema Clinical Trial Trends
4.1 Start Year wise Diabetic Macular Edema Clinical Trials
4.2 Phase wise Diabetic Macular Edema Clinical Trials
4.3 Trial Status wise Diabetic Macular Edema Clinical Trials
4.4 Trial Type wise Diabetic Macular Edema Clinical Trials

5. Diabetic Macular Edema Average Enrollment Trends
5.1 Average Enrollment in Diabetic Macular Edema Trials by Year
5.2 Average Enrollment in Diabetic Macular Edema Trials by Phase
5.3 Average Enrollment in Diabetic Macular Edema Trials by Status
5.4 Average Enrollment in Diabetic Macular Edema Trials by Type of Trial

6. Companies Participating in Diabetic Macular Edema Clinical Trials
6.1 Diabetic Macular Edema Trials by Sponsor Type
6.2 Diabetic Macular Edema Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Diabetic Macular Edema Trials- Phase 1
7.2 Diabetic Macular Edema Trials- Phase 2
7.3 Diabetic Macular Edema Trials- Phase 3
7.4 Diabetic Macular Edema Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Diabetic Macular Edema Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Diabetic Macular Edema Clinical Trials and Enrolment
Figure 5: Europe - Country wise Diabetic Macular Edema Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Diabetic Macular Edema Clinical Trials and Enrolment
Figure 7: North America - Country wise Diabetic Macular Edema Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Diabetic Macular Edema Clinical Trials and Enrolment
Figure 9: Diabetic Macular Edema Clinical Trials by Phase
Figure 10: Diabetic Macular Edema Clinical Trials by Trial Status
Figure 11: Diabetic Macular Edema Clinical Trials by Type
Figure 12: Diabetic Macular Edema Clinical Trials by Sponsor Type
Figure 13: Diabetic Macular Edema Clinical Trials by Leading Sponsors
Figure 14: Diabetic Macular Edema Average Enrollment by Phase
Figure 15: Diabetic Macular Edema Average Enrollment by Trial Status
Figure 16: Diabetic Macular Edema Average Enrollment by Type
Figure 17: Diabetic Macular Edema- Average Enrolment by Type of Sponsors
Figure 18: Diabetic Macular Edema- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Diabetic Macular Edema Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Diabetic Macular Edema Clinical Trials and Enrolment
Table 5: Europe - Country wise Diabetic Macular Edema Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Diabetic Macular Edema Clinical Trials and Enrolment
Table 7: North America - Country wise Diabetic Macular Edema Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Diabetic Macular Edema Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Diabetic Macular Edema Average Enrollment by Phase
Table 15: Diabetic Macular Edema Average Enrollment by Trial Status
Table 16: Diabetic Macular Edema Average Enrollment by Type
Table 17: Diabetic Macular Edema- Average Enrolment by Type of Sponsors
Table 18: Diabetic Macular Edema- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3
  • Aerpio Therapeutics Inc
  • Alimera Sciences Inc
  • Allergan Plc
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Santen Pharmaceutical Co Ltd
  • Valeant Pharmaceuticals International Inc
Note: Product cover images may vary from those shown
Adroll
adroll